Vanguard Group’s Pyxis Oncology PYXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.36M | Sell |
2,149,396
-287,332
| -12% | -$316K | ﹤0.01% | 3487 |
|
|
2025
Q1 | $2.39M | Sell |
2,436,728
-4,425
| -0.2% | -$4.34K | ﹤0.01% | 3435 |
|
|
2024
Q4 | $3.81M | Buy |
2,441,153
+8,200
| +0.3% | +$12.8K | ﹤0.01% | 3371 |
|
|
2024
Q3 | $8.93M | Buy |
2,432,953
+372,509
| +18% | +$1.37M | ﹤0.01% | 3013 |
|
|
2024
Q2 | $6.82M | Buy |
2,060,444
+659,019
| +47% | +$2.18M | ﹤0.01% | 3111 |
|
|
2024
Q1 | $5.97M | Buy |
1,401,425
+94,740
| +7% | +$404K | ﹤0.01% | 3226 |
|
|
2023
Q4 | $2.35M | Buy |
1,306,685
+166,442
| +15% | +$300K | ﹤0.01% | 3547 |
|
|
2023
Q3 | $2.27M | Buy |
1,140,243
+43,794
| +4% | +$87.2K | ﹤0.01% | 3535 |
|
|
2023
Q2 | $2.81M | Buy |
1,096,449
+33,900
| +3% | +$86.8K | ﹤0.01% | 3552 |
|
|
2023
Q1 | $4.26M | Buy |
1,062,549
+144,722
| +16% | +$580K | ﹤0.01% | 3384 |
|
|
2022
Q4 | $1.23M | Buy |
917,827
+443
| +0% | +$594 | ﹤0.01% | 3838 |
|
|
2022
Q3 | $1.81M | Buy |
917,384
+68,304
| +8% | +$135K | ﹤0.01% | 3784 |
|
|
2022
Q2 | $2.02M | Buy |
849,080
+322,771
| +61% | +$768K | ﹤0.01% | 3802 |
|
|
2022
Q1 | $2.13M | Buy |
526,309
+6,011
| +1% | +$24.3K | ﹤0.01% | 3929 |
|
|
2021
Q4 | $5.71M | Buy |
+520,298
| New | +$5.71M | ﹤0.01% | 3533 |
|